Articles from OmniAb, Inc.

OmniAb, Inc. (NASDAQOABI) today announced that management will be participating in two investor conferences during the month of March.

OmniAb, Inc. (NASDAQOABI) today announced that two presentations featuring the Company’s technologies were delivered at the 2024 Antibody Engineering & Therapeutics Conference (AETC) underway in San Diego.

OmniAb, Inc. (NASDAQOABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates.

OmniAb, Inc. (NASDAQOABI) today announced that management will be participating in two investor conferences during the month of November.

OmniAb, Inc. (NASDAQOABI) will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Tuesday, November 12, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

OmniAb, Inc. (NASDAQOABI) today announced that management will be participating in two investor conferences during the month of September.

OmniAb, Inc. (NASDAQOABI) today reported financial results for the three and six months ended June 30, 2024, and provided operating and partner program updates.

OmniAb, Inc. (NASDAQOABI) will report financial results for the three and six months ended June 30, 2024 after the close of the U.S. financial markets on Thursday, August 8, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

OmniAb, Inc. (NASDAQOABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies” in the Journal of Immunology demonstrating that chickens can be genetically engineered to produce functional heavy chain-only single-domain antibodies.

OmniAb, Inc. (NASDAQOABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be presenting a corporate overview on Wednesday, June 5th at 8:00 a.m. Eastern time and will be holding one-on-one meetings with investors.

OmniAb, Inc. (Nasdaq: OABI) today announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier today the Company presented an overview of xPloration, a high-throughput single B-cell screening platform that leverages machine learning and Artificial Intelligence (AI), in a presentation titled “Deep Screening in Harmony with Artificial Intelligence for Bispecific Antibody Discovery.”

OmniAb, Inc. (NASDAQOABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.

OmniAb, Inc. (NASDAQOABI) today announced that management will be participating in five investor conferences during the month of May.

OmniAb, Inc. (NASDAQOABI) will report financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Thursday, May 9, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

OmniAb, Inc. (NASDAQOABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.

OmniAb, Inc. (NASDAQOABI) will report financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Wednesday, March 20, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

OmniAb, Inc. (NASDAQOABI) today announced that management will be participating in two upcoming investor conferences in March.

OmniAb, Inc. (Nasdaq: OABI) announces the presentation of new scientific data on its OmnidAb™ platform, the industry’s first and only transgenic chicken host system producing single domain antibodies (sdAbs), at the 2023 Antibody Engineering & Therapeutics Conference underway in San Diego and hosted by The Antibody Society. The Company presented an overview of OmnidAb and its functionality to industry leaders and prospective customers today in a presentation by Christine Vuong, Ph.D., Senior Scientist, titled “Heavy Chain-Only Transgenic Chickens Produce Human Antibodies with Robust Immune Repertoires and High-Affinity Binding.”

OmniAb, Inc. (Nasdaq: OABI) held its first Research & Technology virtual event earlier today, during which members of the management team reviewed the Company’s technology offerings and highlighted the launch of OmnidAb, the industry’s first and only transgenic chicken producing single domain antibodies (sdAbs). The archived webcast and speaker slides will be available on the Investors portion of OmniAb’s website.

OmniAb, Inc. (NASDAQOABI) today reported financial results for the three and nine months ended September 30, 2023, and provided operating and partner program updates.

OmniAb, Inc. (NASDAQOABI) today announced that management will be participating in two upcoming investor conferences in November.

OmniAb, Inc. (NASDAQOABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb’s Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors.

OmniAb, Inc. (Nasdaq: OABI) announces the agenda for its Research & Technology virtual event to be held on Thursday, November 9th beginning at 11:00 a.m. Eastern time. The two-hour event will include an update on the company’s technology offerings, a review of third quarter financial results, which will be announced earlier that morning, and a Q&A session.

OmniAb, Inc. (Nasdaq: OABI) today announced it will hold a virtual Research & Technology event on Thursday, November 9 beginning at 11:00 a.m. Eastern time. The event is expected to last approximately two hours and will include a review of the company’s latest technology offerings and financial results for the three and nine months ended September 30, 2023, which will be announced earlier that morning.

OmniAb, Inc. (NASDAQOABI) today announced that management will be participating in two upcoming investor conferences in September.

OmniAb, Inc. (NASDAQOABI) today reported financial results for the three and six months ended June 30, 2023, and provided operating and partner program updates.

OmniAb, Inc. (NASDAQOABI) announces that Director Sunil Patel passed away suddenly last week. The Board of Directors and leadership of OmniAb extend their deepest condolences to those who loved and cared for Sunil and express their gratitude for Sunil’s many contributions to OmniAb.

OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 10, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

OmniAb, Inc. (NASDAQOABI) announced the launch of OmniDeep™ at the 19th Annual PEGS Boston Conference and Expo: The Essential Protein Engineering & Cell Therapy Summit. The Company introduced elements of its OmniDeep platform at 1:10 p.m. Eastern time today in a presentation by Bob Chen, Ph.D., OmniAb's Senior Director, Systems Engineering.

OmniAb, Inc. (NASDAQOABI) today reported financial results for the three months ended March 31, 2023, and provided operating and partner program updates.

OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three months ended March 31, 2023 before the open of the U.S. financial markets on Thursday, May 11, 2023 and will hold a conference call that same day beginning at 8:30 a.m. Eastern time.

OmniAb, Inc. (NASDAQOABI) today announced that management will be participating in five upcoming investor conferences in May.

OmniAb, Inc. (NASDAQOABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program updates.

OmniAb, Inc. (NASDAQOABI) will report financial results for the three and 12 months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, March 30, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

OmniAb, Inc. (NASDAQOABI) today announced that management will be participating in three upcoming investor conferences.

OmniAb, Inc. (NASDAQOABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb was part of Ligand Pharmaceuticals Incorporated NASDAQ: LGNDNASDAQLGND)

OmniAb, Inc. (NASDAQOABI) today announced that management will be participating in two upcoming investor conferences.

OmniAb, Inc. (NASDAQOABI) today announced its Chief Executive Officer Matt Foehr will ring the opening bell of the Nasdaq Stock Market in a ceremony today at 9:30 a.m. Eastern time. He will be joined by members of OmniAb’s leadership team and Board of Directors to celebrate its listing on the exchange, where regular trading will begin under the ticker OABI on November 2, 2022.

OmniAb, Inc. (NASDAQOABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated NASDAQ: LGNDNASDAQLGND)(NASDAQ: AHPANASDAQAHPA, resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol “OABI.”